+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Matrix metalloproteinases in pathophysiology and treatment of heart failure



Matrix metalloproteinases in pathophysiology and treatment of heart failure



Lancet 357(9257): 654-655




(PDF emailed within 0-6 h: $19.90)

Accession: 046631377

Download citation: RISBibTeXText

PMID: 11247546

DOI: 10.1016/s0140-6736(00)04151-9


Related references

Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and heart failure outcomes. International Journal of Cardiology 151(2): 237-239, 2012

Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure. International Journal of Cardiology 145(3): 438-443, 2011

Cardiac matrix remodelling in congestive heart failure: the role of matrix metalloproteinases. Clinical and Investigative Medicine. Medecine Clinique et Experimentale 27(2): 93-100, 2004

Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure. Zhonghua Yi Xue Za Zhi 86(24): 1693-1696, 2006

Treatment with spironolactone for 24 weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology. Canadian Journal of Cardiology 25(9): 523-526, 2009

The role of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the pathophysiology of neurodegeneration: a literature study. Journal of Alzheimer's Disease 37(2): 273-283, 2014

Matrix metalloproteinases: not-so-innocent bystanders in heart failure. Journal of Clinical Investigation 106(7): 827-828, 2000

Matrix Metalloproteinases in Myocardial Infarction and Heart Failure. Progress in Molecular Biology and Translational Science 147: 75-100, 2017

Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 113(17): 2089-2096, 2006

TNF-a and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. American Journal of Physiology 282(4): 288-H1295, 2002

Dynamic role of extracellular matrix metalloproteinases in heart failure. Cardiovascular Pathology 7(3): 153-159, 1998

Treatment and disease state of heart failure. Problem and availability of a cardiotonic treatment from the viewpoint of the pathophysiology of chronic heart failure. Nihon Naika Gakkai Zasshi 84(9): 1465-1469, 1995

Myocardial remodelling and matrix metalloproteinases in heart failure: turmoil within the interstitium. Annals of Medicine 33(9): 623-634, 2002

TNF-alpha and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. American Journal of Physiology. Heart and Circulatory Physiology 282(4): H1288-H1295, 2002

The role of matrix metalloproteinases and cardiac fibroblasts in heart failure progression. European Heart Journal 24(Abstract Supplement): 656, August-September, 2003